CD274 and breast cancer: In this regard, preliminary results from the phase II randomized KATE2 trial indicate an improved OS in PD-L1-positive patients affected by locally advanced or metastatic BC treated with the combination of atezolizumab and ado-trastuzumab emtansine (T-DM1) [56].